We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Theracryf Plc (TCF) Ordinary 0.25p

Sell:0.90p Buy:1.00p 0 Change: No change
Market closed Prices as at close on 13 June 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Miscellaneous

Evgen Pharma plc Ordinary 0.25p

Type:
Miscellaneous
Shareholder action required:
Yes
Status:
Update Pending
Details (last updated 20 Mar 2024)

What is happening?

 

Evgen Pharma (EVG) have announced their intention to raise up to £1.85m via a Placing (for Institutional Investors) and a Retail Offer (for Individual Investors).


Evgen Pharma (EVG) have decided not to issue a Prospectus as part of the fundraising. This means that the Retail Offer has been limited to the Sterling equivalent of €8 million and may only be open for a number of hours. It also means that information relating to the fundraising is limited to the Company announcement.

 

• Applications are due to close at 11am on Wednesday 03 April. Due to the nature of the fundraising, applications can close at any time and without prior warning.

 

• Shares are being offered at a fixed price of 1 pence.


• The minimum application for the Retail Offer is £250.


• By applying for shares in the Retail Offer you are deemed to have read, understood and agreed to the HL Retail Offer Risk Warnings, Terms and Conditions and the Company Announcement.


• Hargreaves Lansdown will receive 0.6% commission from the Issuer as part of the Offer.

 

Enterprise Investment Scheme (EIS) Shares

As part of the Retail Offer, you are able to elect to have your shares designated as Enterprise Investment Scheme (EIS) shares. This is a government scheme which can confer certain tax benefits to an investor in eligible companies.


The conditions for EIS Relief are complex and relevant investors are recommended to seek their own professional advice before investing, in order that they may fully understand how the relief legislation may apply in their individual circumstances. Any investor who is in any doubt as to their taxation position under the EIS legislation, or who is subject to tax in a jurisdiction other than the UK, should consult an appropriate professional adviser.


If you wish to apply for EIS shares, please add a note in the comments section of the application. Please note, EIS shares can only be held in an HL Fund and Share Account.

 

What are my options?

 

Option 1 – Do Nothing. If you do not return an election by the deadline of 11am on Wednesday 03 April, the Offer will lapse.


Option 2 – You can choose to buy new Shares at 1 pence. If you wish to submit an order outside of the product you currently hold your shares, please leave a note in the comments section of the application.

 

When do I have to decide by?


Any instruction to participate in the Retail Offer must be received by 11am on Wednesday 03 April. If no instruction is received the Offer will lapse.

 

Before submitting an instruction, you should carefully read the Company Announcement, HL Retail Offer Risk Warnings & Terms and Conditions which are attached to the Retail Offer notification. You can find this in the Secure Messaging Centre of your online account.

 

By submitting an instruction, you are deemed to have read and understood these documents as well as agreed to any terms within.


What happens after I apply?

 

If you apply for shares you will receive two Secure Messages. The first will confirm your application and be sent shortly after 12pm on Wednesday 03 April. The second will confirm how many shares you have been allocated and be sent once the results have been announced on Thursday 04 April.


You can view your application in the Pending Orders tab of your online account from 12pm on Thursday 04 April.


Your new shares will be credited shortly before 8am on Friday 05 April. This may be delayed in the event the company does not deliver your shares to us by this time.


To assist the Company during the allocation process, we may be required to disclose the number of Evgen Pharma (EVG) shares you hold with Hargreaves Lansdown. We will do this by calculating the shares held in your Hargreaves Lansdown account at the close of business on Tuesday 19 March.


It should be noted that a subscription for the Retail Shares and any investment in the Company carry a number of risks. Investors should make their own investigations into the merits of an investment in the Company. This message is not personal advice and is a summary of the Evgen Pharma (EVG) announcement.


If you require any assistance, please contact our Helpdesk on 0117 900 9000.

×
Sell:0.90p
Buy:1.00p
Change: No change
Market closed Prices as at close on 13 June 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Miscellaneous

Evgen Pharma plc Ordinary 0.25p

Type:
Miscellaneous
Shareholder action required:
Yes
Status:
Update Pending
Details (last updated 20 Mar 2024)

What is happening?

 

Evgen Pharma (EVG) have announced their intention to raise up to £1.85m via a Placing (for Institutional Investors) and a Retail Offer (for Individual Investors).


Evgen Pharma (EVG) have decided not to issue a Prospectus as part of the fundraising. This means that the Retail Offer has been limited to the Sterling equivalent of €8 million and may only be open for a number of hours. It also means that information relating to the fundraising is limited to the Company announcement.

 

• Applications are due to close at 11am on Wednesday 03 April. Due to the nature of the fundraising, applications can close at any time and without prior warning.

 

• Shares are being offered at a fixed price of 1 pence.


• The minimum application for the Retail Offer is £250.


• By applying for shares in the Retail Offer you are deemed to have read, understood and agreed to the HL Retail Offer Risk Warnings, Terms and Conditions and the Company Announcement.


• Hargreaves Lansdown will receive 0.6% commission from the Issuer as part of the Offer.

 

Enterprise Investment Scheme (EIS) Shares

As part of the Retail Offer, you are able to elect to have your shares designated as Enterprise Investment Scheme (EIS) shares. This is a government scheme which can confer certain tax benefits to an investor in eligible companies.


The conditions for EIS Relief are complex and relevant investors are recommended to seek their own professional advice before investing, in order that they may fully understand how the relief legislation may apply in their individual circumstances. Any investor who is in any doubt as to their taxation position under the EIS legislation, or who is subject to tax in a jurisdiction other than the UK, should consult an appropriate professional adviser.


If you wish to apply for EIS shares, please add a note in the comments section of the application. Please note, EIS shares can only be held in an HL Fund and Share Account.

 

What are my options?

 

Option 1 – Do Nothing. If you do not return an election by the deadline of 11am on Wednesday 03 April, the Offer will lapse.


Option 2 – You can choose to buy new Shares at 1 pence. If you wish to submit an order outside of the product you currently hold your shares, please leave a note in the comments section of the application.

 

When do I have to decide by?


Any instruction to participate in the Retail Offer must be received by 11am on Wednesday 03 April. If no instruction is received the Offer will lapse.

 

Before submitting an instruction, you should carefully read the Company Announcement, HL Retail Offer Risk Warnings & Terms and Conditions which are attached to the Retail Offer notification. You can find this in the Secure Messaging Centre of your online account.

 

By submitting an instruction, you are deemed to have read and understood these documents as well as agreed to any terms within.


What happens after I apply?

 

If you apply for shares you will receive two Secure Messages. The first will confirm your application and be sent shortly after 12pm on Wednesday 03 April. The second will confirm how many shares you have been allocated and be sent once the results have been announced on Thursday 04 April.


You can view your application in the Pending Orders tab of your online account from 12pm on Thursday 04 April.


Your new shares will be credited shortly before 8am on Friday 05 April. This may be delayed in the event the company does not deliver your shares to us by this time.


To assist the Company during the allocation process, we may be required to disclose the number of Evgen Pharma (EVG) shares you hold with Hargreaves Lansdown. We will do this by calculating the shares held in your Hargreaves Lansdown account at the close of business on Tuesday 19 March.


It should be noted that a subscription for the Retail Shares and any investment in the Company carry a number of risks. Investors should make their own investigations into the merits of an investment in the Company. This message is not personal advice and is a summary of the Evgen Pharma (EVG) announcement.


If you require any assistance, please contact our Helpdesk on 0117 900 9000.

×
Sell:0.90p
Buy:1.00p
Change: No change
Market closed Prices as at close on 13 June 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Miscellaneous

Evgen Pharma plc Ordinary 0.25p

Type:
Miscellaneous
Shareholder action required:
Yes
Status:
Update Pending
Details (last updated 20 Mar 2024)

What is happening?

 

Evgen Pharma (EVG) have announced their intention to raise up to £1.85m via a Placing (for Institutional Investors) and a Retail Offer (for Individual Investors).


Evgen Pharma (EVG) have decided not to issue a Prospectus as part of the fundraising. This means that the Retail Offer has been limited to the Sterling equivalent of €8 million and may only be open for a number of hours. It also means that information relating to the fundraising is limited to the Company announcement.

 

• Applications are due to close at 11am on Wednesday 03 April. Due to the nature of the fundraising, applications can close at any time and without prior warning.

 

• Shares are being offered at a fixed price of 1 pence.


• The minimum application for the Retail Offer is £250.


• By applying for shares in the Retail Offer you are deemed to have read, understood and agreed to the HL Retail Offer Risk Warnings, Terms and Conditions and the Company Announcement.


• Hargreaves Lansdown will receive 0.6% commission from the Issuer as part of the Offer.

 

Enterprise Investment Scheme (EIS) Shares

As part of the Retail Offer, you are able to elect to have your shares designated as Enterprise Investment Scheme (EIS) shares. This is a government scheme which can confer certain tax benefits to an investor in eligible companies.


The conditions for EIS Relief are complex and relevant investors are recommended to seek their own professional advice before investing, in order that they may fully understand how the relief legislation may apply in their individual circumstances. Any investor who is in any doubt as to their taxation position under the EIS legislation, or who is subject to tax in a jurisdiction other than the UK, should consult an appropriate professional adviser.


If you wish to apply for EIS shares, please add a note in the comments section of the application. Please note, EIS shares can only be held in an HL Fund and Share Account.

 

What are my options?

 

Option 1 – Do Nothing. If you do not return an election by the deadline of 11am on Wednesday 03 April, the Offer will lapse.


Option 2 – You can choose to buy new Shares at 1 pence. If you wish to submit an order outside of the product you currently hold your shares, please leave a note in the comments section of the application.

 

When do I have to decide by?


Any instruction to participate in the Retail Offer must be received by 11am on Wednesday 03 April. If no instruction is received the Offer will lapse.

 

Before submitting an instruction, you should carefully read the Company Announcement, HL Retail Offer Risk Warnings & Terms and Conditions which are attached to the Retail Offer notification. You can find this in the Secure Messaging Centre of your online account.

 

By submitting an instruction, you are deemed to have read and understood these documents as well as agreed to any terms within.


What happens after I apply?

 

If you apply for shares you will receive two Secure Messages. The first will confirm your application and be sent shortly after 12pm on Wednesday 03 April. The second will confirm how many shares you have been allocated and be sent once the results have been announced on Thursday 04 April.


You can view your application in the Pending Orders tab of your online account from 12pm on Thursday 04 April.


Your new shares will be credited shortly before 8am on Friday 05 April. This may be delayed in the event the company does not deliver your shares to us by this time.


To assist the Company during the allocation process, we may be required to disclose the number of Evgen Pharma (EVG) shares you hold with Hargreaves Lansdown. We will do this by calculating the shares held in your Hargreaves Lansdown account at the close of business on Tuesday 19 March.


It should be noted that a subscription for the Retail Shares and any investment in the Company carry a number of risks. Investors should make their own investigations into the merits of an investment in the Company. This message is not personal advice and is a summary of the Evgen Pharma (EVG) announcement.


If you require any assistance, please contact our Helpdesk on 0117 900 9000.

×
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Theracryf PLC, formerly Evgen Pharma plc, is a clinical-stage therapeutics company. The Company is engaged in developing a new generation of therapeutics in oncology and behavioral brain disorders. Its pipeline and lead compound SFX-01 is derived from its proprietary Sulforadex technology. Its Sulforadex technology synthesizes sulforaphane into an active, stable, and solid form pharmaceutical ingredient, unlocking its medical and commercial potential. SFX-01 is a complex of sulforaphane and alpha-cyclodextrin formulated as a stable tablet. The Company has a candidate orexin 1 antagonist at late preclinical stage targeting addictive behaviors. It also has a candidate molecule DAT inhibitor at late preclinical stage targeting fatigue and narcolepsy.

Contact details

Address:
Suite 24G13 - Block 24 Alderley Park
Congleton Road, Nether Alderley
NETHERTON
SK10 4TG
United Kingdom
Telephone:
+44 (01625) 315090
Website:
https://evgen.com/

Important dates

Future events
There are no future events available.
Past events
Final results 28 May 2024 28/05/24
General meeting 04 April 2024 04/04/24

General stock information

EPIC:
TCF
ISIN:
GB00BSVYN304
Market cap:
£4.06 million
Shares in issue:
427.35 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Huw Jones
    Chief Executive Officer, Executive Director
  • Toni Hanninen
    Chief Financial Officer, Director
  • Richard Moulson
    Executive Director
  • Glen Clack
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.